Medicine · Diabetes & Endocrinology
A paradigm shift in diabetes-related mortality has been documented, with cardiovascular disease no longer the dominant cause of death among people with type 2 diabetes. The analysis by Magliano and colleagues, published in The Lancet Diabetes & Endocrinology, reveals that cardiovascular mortality declined in every assessed jurisdiction over the past decade, reflecting the impact of GLP-1 receptor agonists and SGLT2 inhibitors. For a clinical leader focused on diabetes complications and advancing care standards in India, this finding reinforces the importance of integrating cardioprotective therapies into routine diabetes management to further reduce mortality.
Novelty: 88%
Rigor: 92%
Significance: 95%
Validity: 91%
Clarity: 90%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
